ABBV-101

Phase 1Small molecule

AbbVie

ABBV-101 is one of 10 small molecule programs targeting Hematologic Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic CancerActive, not recruiting

Hematologic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Hematologic Cancer

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

4 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

12 3

Fludara

Sanofi

Phase 2

2 4

Darzalex

Johnson & Johnson

Phase 2

1 5

Mesnex

BBaxter Healthcare Corporation

Phase 2

1 6

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 7

Venclexta

AbbVie

Phase 1

1 8

Interleukin 2

EEssen Biotech

Phase 2

1 9

IDP-023

IIndapta Therapeutics, INC.

Phase 2

1 10

ABBV-101

AbbVie

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Active, not recruiting

Hematologic Cancer

NCT05753501

Clinical

Trials by Indication[1]

Adult1 trial

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Completed· AbbVie logo

AbbVie·Phase 1·NCT06887010·17 enrolled

Hematologic Cancer1 trial

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05753501·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABBV-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Adult1 trial

Hematologic Cancer1 trial

References

Drug Info

Quick Facts

Related News